GLPwatch
Immunotherapies in diabetes mellitus type 1.
Med Clin North Am · 2012
Last updated 2026-05-28Type 1 diabetes is an autoimmune condition where the body attacks insulin-producing cells in the pancreas. While lab studies of immune-based treatments have shown promise, these therapies have not yet worked in human trials. This review looks at past attempts to use immunotherapy at different stages of the disease and discusses potential future directions.
AI summary of the abstract below.
| Journal | Med Clin North Am, 2012 |
|---|---|
| Citations | 10 |
| Relative citation ratio | 0.29 |
| NIH percentile | 18 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the immunopathogenesis of this disease has greatly increased. Immunotherapies that can change the course of immune-mediated destruction and preserve and possibly regenerate the pancreatic beta cells seem to be promising in preclinical trials but so far have been unsuccessful in human studies. This article reviews the important immune interventions for type 1 diabetes that have been tried so far targeting the different stages of disease development and provides an insight into what the future might hold.
Verbatim abstract via PubMed 22703858 ↗